Blueprint Medicines Corporation
BPMC
$101.50
$1.161.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 55.45% | 103.41% | 126.61% | 139.98% | 51.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.45% | 103.41% | 126.61% | 139.98% | 51.87% |
| Cost of Revenue | -12.19% | 3,363.72% | -57.57% | 113.47% | -28.63% |
| Gross Profit | 57.77% | 93.64% | 142.73% | 141.73% | 57.99% |
| SG&A Expenses | 14.66% | 21.60% | 27.12% | 24.20% | 17.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.89% | 5.93% | -4.52% | -2.34% | -6.70% |
| Operating Income | 47.88% | 60.80% | 62.03% | 66.37% | 36.54% |
| Income Before Tax | -98.56% | 55.54% | 58.06% | 62.37% | 169.22% |
| Income Tax Expenses | 338.33% | 1,001.64% | 38.58% | -46.32% | -65.38% |
| Earnings from Continuing Operations | -99.44% | 54.96% | 57.91% | 62.35% | 168.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -99.44% | 54.96% | 57.91% | 62.35% | 168.80% |
| EBIT | 47.88% | 60.80% | 62.03% | 66.37% | 36.54% |
| EBITDA | 50.51% | 64.08% | 64.23% | 68.31% | 38.59% |
| EPS Basic | -99.47% | 56.88% | 59.70% | 63.75% | 167.18% |
| Normalized Basic EPS | 44.46% | 45.80% | 59.84% | 63.76% | 36.18% |
| EPS Diluted | -99.45% | 56.88% | 59.70% | 63.54% | 164.97% |
| Normalized Diluted EPS | 44.57% | 45.80% | 59.84% | 63.76% | 38.40% |
| Average Basic Shares Outstanding | 4.09% | 4.45% | 4.44% | 3.86% | 2.42% |
| Average Diluted Shares Outstanding | 4.27% | 4.45% | 4.44% | 3.86% | 6.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |